Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Angiodynamics Inc. (ANGO:NASDAQ), powered by AI.
Angiodynamics Inc. is currently trading at $12.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Angiodynamics Inc. on Alpha Lenz.
Angiodynamics Inc.'s P/E ratio is -14.6.
“Angiodynamics Inc. trades at a P/E of -14.6 (undervalued) with modest ROE of -17.5%.”
Ask for details →Angiodynamics Inc. is a prominent player in the medical device industry, specializing in the development, manufacture, and sale of minimally invasive medical, surgical, and diagnostic devices used by healthcare professionals around the globe. Their product portfolio spans several key areas, including oncology, vascular interventions, and peripheral disease solutions, focusing on innovative technologies that enhance patient care and improve medical outcomes. Angiodynamics places a strong emphasis on research and development, driving advancements in products such as radiofrequency ablation devices, angiographic catheters, and other vascular access products. With a widespread impact across various healthcare sectors, Angiodynamics is committed to addressing critical medical challenges and enhancing operational efficiency in surgical procedures. The company's strategic initiatives and collaborations aim to expand their market presence and influence, continuously adapting to the evolving needs of medical facilities and professionals. As a crucial contributor to the healthcare technology landscape, Angiodynamics plays a vital role in facilitating advancements in patient-focused treatment modalities, solidifying its importance within the healthcare field.
“Angiodynamics Inc. trades at a P/E of -14.6 (undervalued) with modest ROE of -17.5%.”
Ask for details →Angiodynamics Inc. (ticker: ANGO) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 675 employees. Market cap is $496M.
The current price is $12.15 with a P/E ratio of -14.6x and P/B of 2.71x.
ROE is -17.50% and operating margin is -8.23%. Annual revenue is $292M.